User contributions
From WikiPathways
(Latest | Earliest) View (newer 50) (older 50) (20 | 50 | 100 | 250 | 500)
- 18:37, 13 May 2020 WP4846 (Discussion edited)
- 18:37, 13 May 2020 WP4846 (Discussion edited)
- 18:37, 13 May 2020 N Incorrect molecule types (3) (New page: I had not done the human proteins yet. Will change that now.) (top)
- 16:54, 13 May 2020 Homo sapiens:SARS-CoV-2 and COVID-19 pathway (Added a new gene mentioned.)
- 13:37, 13 May 2020 DeSl (Correct Wikidata item)
- 12:43, 13 May 2020 Disease/COVIDPathways (Added a new pathway stub.)
- 08:35, 11 May 2020 Egonw/BioschemasTest (top)
- 08:34, 11 May 2020 N Egonw/BioschemasTest (New page: <script> </script>)
- 11:55, 9 May 2020 Homo sapiens:Unfolded protein response (Not a mim-conversion)
- 11:30, 9 May 2020 Homo sapiens:Unfolded protein response
- 10:18, 9 May 2020 Homo sapiens:Mitochondrial complex II assembly (Replaced a secondary ChEBI identifiers with a primary identifier.)
- 10:17, 9 May 2020 Homo sapiens:Neuroinflammation (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 19:42, 8 May 2020 Disease/COVIDPathways
- 19:18, 6 May 2020 Homo sapiens:Linoleic acid metabolism affected by SARS-CoV-2 (Made the full membrane visible)
- 16:07, 3 May 2020 Homo sapiens:COVID-19 adverse outcome pathway (Added missing @Type annotation)
- 16:05, 3 May 2020 Homo sapiens:SARS-CoV-2 and COVID-19 pathway (Added missing @Type annotation)
- 06:48, 3 May 2020 Homo sapiens:Disruption of postsynaptic signaling by CNV (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:47, 3 May 2020 Homo sapiens:Influence of laminopathies on Wnt signaling (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:45, 3 May 2020 Homo sapiens:EGFR tyrosine kinase inhibitor resistance (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:42, 3 May 2020 Homo sapiens:3q29 copy number variation syndrome (Replaced a secondary ChEBI identifiers with a primary identifier.)
- 06:37, 3 May 2020 Homo sapiens:Adverse outcome pathway for mitochondrial complex 1 (C1) inhibition (Replaced a secondary ChEBI identifiers with a primary identifier.)
- 15:10, 2 May 2020 Homo sapiens:Peroxiredoxin 2 induced ovarian failure (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 14:23, 2 May 2020 Homo sapiens:Kisspeptin/kisspeptin receptor system in the ovary (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 14:21, 2 May 2020 Homo sapiens:Mammalian disorder of sexual development (Replaced a secondary ChEBI identifiers with a primary identifier.)
- 14:20, 2 May 2020 Mus musculus:Peroxiredoxin 2 induced ovarian failure (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 09:33, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Second round of manual cleanup)
- 09:26, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (First round of manual clean up of the Biopax xml)
- 09:06, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (More PubMed identifiers)
- 08:51, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Added more PubMed identifiers)
- 08:37, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (More unicode fixes and added missing PubMed identifiers.)
- 08:28, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Fixed more unicode issues)
- 08:18, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Fixed unicode issues in a few references)
- 08:03, 2 May 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 07:55, 2 May 2020 Homo sapiens:Mammalian disorder of sexual development (Not a mim-conversion)
- 07:54, 2 May 2020 Homo sapiens:Regucalcin in proximal tubule epithelial kidney cells (Not a mim-conversion)
- 07:52, 2 May 2020 Homo sapiens:Mevalonate arm of cholesterol biosynthesis pathway with inhibitors (Replaced three InChIKeys with PubChem-compound identifiers.)
- 07:15, 2 May 2020 Homo sapiens:Purinergic signaling (Removed whitespace from PubChem identifiers.)
- 07:12, 2 May 2020 Homo sapiens:Mammalian disorder of sexual development (Not a mim-conversion)
- 07:08, 2 May 2020 Homo sapiens:FGFR3 signaling in chondrocyte proliferation and terminal differentiation (Not a mim-conversion)
- 07:07, 2 May 2020 Homo sapiens:Glycosaminoglycan degradation (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 07:02, 2 May 2020 Homo sapiens:Purinergic signaling (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:58, 2 May 2020 Homo sapiens:Regucalcin in proximal tubule epithelial kidney cells (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:44, 2 May 2020 Homo sapiens:Cholesterol biosynthesis with skeletal dysplasias (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 06:29, 2 May 2020 Homo sapiens:Autosomal recessive osteopetrosis pathways (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 15:32, 30 April 2020 Homo sapiens:FGFR3 signaling in chondrocyte proliferation and terminal differentiation (Not a mim-conversion)
- 15:31, 30 April 2020 Homo sapiens:Mammalian disorder of sexual development (Not a mim-conversion)
- 15:30, 30 April 2020 Homo sapiens:Mevalonate arm of cholesterol biosynthesis pathway with inhibitors (Replaced an InChIKey with a PubChem CID.)
- 15:25, 30 April 2020 Homo sapiens:Type I collagen synthesis in the context of osteogenesis imperfecta (Replaced secondary ChEBI identifiers with a primary identifiers.)
- 15:23, 30 April 2020 Homo sapiens:Overlap between signal transduction pathways contributing to LMNA laminopathies (Replaced a secondary ChEBI identifiers with a primary identifier.)
(Latest | Earliest) View (newer 50) (older 50) (20 | 50 | 100 | 250 | 500)
